SynthesisFrontiers in medicine2025
Sarcopenia in end-stage lung disease patients: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CT-derived skeletal muscle predicts lung transplant approval.JHLT open · 2026Article
- Differential predictive value of phase angle for malnutrition and physical impairment in respiratory patients: the moderating role of sarcopenia.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is usually an age-related disease in the elderly, which also affects patients with end-stage lung disease (ELD), such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary hypertension, significantly affects disease progression and clinical outcomes. Currently, there are various methods for quantifying sarcopenia through muscle mass assessment. This study aimed to evaluate the prevalence of sarcopenia in patients with end-stage lung diseases using meta-analysis and to explore its influencing factors and clinical implications. A systematic search was conducted in English databases, including PubMed, Web of Science (WOS), Embase, Cochrane Library, CINAHL, and Scopus. Two researchers independently assessed study quality using the JBI Critical Appraisal Checklist for Analytical Cross Sectional Studies. Data analysis was performed using Stata 18.0 and R 4.4.3 software. The pooled prevalence of sarcopenia in ELD patients was calculated using a random-effects model, with subgroup analyses to identify sources of heterogeneity. Twenty-four cross-sectional studies involving 6,800 patients were included. The pooled prevalence of sarcopenia in ELD patients was 31.6% (95% CI: 26.5-36.8%). Subgroup analyses revealed higher sarcopenia prevalence in patients aged ≥70 years (vs. <70 years), males (vs. Females), those diagnosed using AWGS2019 criteria (vs.other criteria), dual-energy X-ray absorptiometry (DXA; vs. bioelectrical impedance analysis [BIA]), Asian populations (vs. European/North American populations), and COPD patients (vs. IPF/ILD patients). Sarcopenia is prevalent among patients with ELD, with its prevalence varying across different populations due to multiple influencing factors, resulting in distinct clinical outcomes. It is recommended to implement targeted intervention strategies based on these factors to reduce the incidence of sarcopenia and enhance the quality of life. Systematic review registration: Identifier, CRD420251028682 (PROSPERO).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.